Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 492

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

Open access
Greenberg, Michael E., Lai, Michael H., Hartel, Gunter F., Wichems, Christine H., Gittleson, Charmaine, Bennet, Jillian, Dawson, Gail, Hu, Wilson, Leggio, Connie, Washington, Diane, Basser, Russell L.·2009·New England Journal of Medicine

Abstract

BACKGROUND: A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia. METHODS: We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups (<50 years and >or=50 years), were enrolled and underwent randomization to receive either 15 microg or 30 microg of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer. RESULTS: By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-microg dose and in 106 of 119 subjects (89.1%) who received the 30-microg dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity. CONCLUSIONS: A single 15-microg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions. (ClinicalTrials.gov number, NCT00938639).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0907413

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 492

Metadata

Authors
Greenberg, M. E., Lai, M. H., Hartel, G. F., Wichems, C. H., Gittleson, C., Bennet, J., Dawson, G., Hu, W., Leggio, C., Washington, D., & Basser, R. L.
Venue
New England Journal of Medicine
Published
2009-12-17
Volume
361
Issue
25
Pages
2405-2413
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2170155793
Cited by
492
References
12
FWCI
72.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Response to a Monovalent 2009 Influenza A (H1N1) Vaccine. https://app.cochat.ai/papers/10.1056/nejmoa0907413
The paper
Greenberg, M. E., Lai, M. H., Hartel, G. F., Wichems, C. H., Gittleson, C., Bennet, J., Dawson, G., Hu, W., Leggio, C., Washington, D., & Basser, R. L. (2009). Response to a Monovalent 2009 Influenza A (H1N1) Vaccine. New England Journal of Medicine. https://doi.org/10.1056/nejmoa0907413

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.